Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineNo recent work listed

Yanqing Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6812-2811; OpenAlex author ID A5100360924. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 1 paper

Papers 2

  1. The predictive value of prognosis and therapeutic response for STAT family in pancreatic cancer. Last author DOI 10.1016/j.heliyon.2023.e16150↗
  2. Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells. Co-author DOI 10.1016/j.fct.2020.111919↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tao Li · 1 shared paper, 2021 · strength 0.19
  2. Zhuangzhuang Jiang · 1 shared paper, 2021 · strength 0.19
  3. LU Hai-yan · 1 shared paper, 2023 · strength 0.17
  4. Haibo Wang · 1 shared paper, 2023 · strength 0.17
  5. Zhengfei He · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.